

REC'D PTO 17 OCT 2005

Docket No.: 05986/100K560-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Blas Frangione et al.

Application No.: 10/540,294

Confirmation No.: 8280

Filed: June 20, 2005

Art Unit: N/A

For: METHODS FOR TREATING AMYLOID
DISEASES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)). Accordingly, it is believed no fee is due.

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information


Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 12, 2005

Respectfully submitted,

By 
Heather Morehouse Ettinger, Ph.D.

Registration No.: 51,658
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(206) 262-8919
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/540,294-Conf. #8280
				Filing Date	June 20, 2005
				First Named Inventor	Blas Frangione
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05986/100K560-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-U.S. 2002/0037290-A1	03-28-2002	Armen	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	-WO-98/15179 A1	04-16-1998	University of Washington		
	BB	-WO-02/11669 A2	02-14-2002	Antigenics		
	BC	-WO-99/27949 A1	06-10-1999	Brigham and Women's Hospital		
	BD	-WO-01/90182 A2	11-29-2001	New York University		
	BE	-WO-99/27944 A1	06-10-1999	Athena Neurosciences, Inc.		
	BF	-WO-95/31966 A1	11-30-1995	Novavax, Inc.		
	BG	-WO-96/39834 A1	12-19-1996	New York University		
	BH	-WO-00/72800 A2	12-07-2000	Smithkline Beecham Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Pepys, et al., Targeted Pharmacological Depletion of Serum Amyloid P Component for Treatment of Human Amyloidosis, Nature vol. 417, (2002) pp. 254-259.	
	CB	Seubert et al., Nature 359:355-327 (1992)	
	CC	Shoji et al., Science 258:126-129 (1992)	
	CD	Ji et al., Journal of Alzheimer's Disease 2001;3:23-30	
	CE	Shibata et al., J Clin Invest 2000;106:1489-99	
	CF	Gherzi-Egea et al., J Neurochem 1996;67(2):880-3	
	CG	Zlokovic et al., Biochem Biophys Res Commun 1994;205:1431-1437	
	CH	Ghiso et al., Biochem J 1993;293:27-30	
	CI	Ghiso et al., Mol Neurobiol. 1994;8:49-64	
	CJ	Koudinov et al., Biochem Biophys Res Commun 1994;205:1164-1171	
	CK	Klokovic et al., Proc Natl Acad Sci USA 1996;93:4229-4234	
	CL	Jarrett et al., Cell 1993;73:1055-1058	
	CM	Jarrett et al., Biochemistry 1993;32:4693-4697	
	CN	Soto et al., Nat Med 1998;4:822-826	
	CO	Sigurdsson et al., J Neuropath Exp Neurol 2000;59:11-17	
	CP	Findeis MA., Biochim Biophys Acta 2000;1502:76-84	
	CQ	Frenkel et al., J Neuroimmunol 1999;95:136-142	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,294-Conf. #8280
				Filing Date	June 20, 2005
				First Named Inventor	Blas Frangione
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05986/100K560-US1

	CR	Ylera et al. (Biochem. Biophys. Res. Comm. 2002;200:1583-1588)	
	CS	Carro et al., Nat Med 2002;8:1390-7	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--